{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-017765","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.117727+00:00","generated_at":"2026-06-20T07:23:32.233657+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Centessa enters ATM equity offering facility for up to $125M","bullets":["Entered Sales Agreement with SVB Securities for at-the-market offering of ADS representing ordinary shares.","Company may sell up to $125M of ADS at its discretion; no minimum offering amount required.","SVB Securities to receive 3% commission on gross proceeds; company reimburses legal fees up to $150k.","Net proceeds expected for working capital, capex, and general corporate purposes.","No assurance of any sales; offering terminates upon full sale or agreement termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-017765","json":"https://secwatch.observer/filing/0001193125-23-017765.json","markdown":"https://secwatch.observer/filing/0001193125-23-017765.md","text":"https://secwatch.observer/filing/0001193125-23-017765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/0001193125-23-017765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/d418242d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:23:32.233657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c74e1f95add152414ce648d3f403345121d43411","claim":"Centessa Pharmaceuticals plc entered into Sales Agreement with SVB Securities LLC valued at up to $125 million (effective 2023-01-27).","evidence_excerpt":"On January 27, 2023, Centessa Pharmaceuticals plc (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB Securities”) with respect to an at-the-market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through SVB Securities, acting as the Company’s sales agent, up to $125 million of the Company’s American Depositary Shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/0001193125-23-017765-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"SVB Securities LLC"},{"label":"Value","value":"up to $125 million"},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}